Recognition of biomarker identified high-risk patients in the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban study resulting in a protocol amendment

American Heart Journal

Volumn 169, Issue 1, 2015, Pages 186-187

  Cohen, Alexander T ^a   Harrington, Robert ^b   Goldhaber, Samuel Z ^c   Hull, Russell ^d   Gibson, C M ^d   Hernandez, Adrian F ^e   Gold, Alex ^f  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f Portola Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETRIXABAN; BIOLOGICAL MARKER; D DIMER; ENOXAPARIN; ANTICOAGULANT AGENT; BENZAMIDE DERIVATIVE; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE;

ACUTE DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; LETTER; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; BENZAMIDES; ENOXAPARIN; FACTOR XA INHIBITORS; HUMANS; PYRIDINES; VENOUS THROMBOEMBOLISM;

EID: 84925884552     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.09.004     Document Type: Letter

References (7)

1. Cohen AT, Harrington R, Goldhaber SZ, et al. The design and rationale for theAcute Medically IllVenous ThromboembolismPrevention with Extended Duration Betrixaban (APEX) study. Am Heart J 2014;167(3):335-41.
2. Cohen AT, Spiro TE, Spyropoulos AC, et al. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost 2014;12(4):479-87.
3. Desjardins L, Bara L, Boutitie F, et al. Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. Arch Pathol Lab Med 2004;128(5): 519-26.
4. Mebazaa A, Spiro TE, Buller HR, et al. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. Circulation 2014;130(5):410-8.
5. Fan J, Li X, Cheng Y, et al. Measurement of D-dimer as aid in risk evaluation of VTE in elderly patients hospitalized for acute illness: a prospective, multicenter study in China. Clin Invest Med 2011;34(2): E96-104.
6. Yi X, Lin J, Han Z, et al. The incidence of venous thromboembolism following stroke and its risk factors in eastern China. J Thromb Thrombolysis 2012;34(2):269-75.
7. Temple DR. Enrichment strategies for clinical trials to support approval of human drugs and biological products. United States Food and Drug Administration. 2012. [www.fda.gov/downloads/Drugs/./ Guidances/UCM332181.pdf].